Lenz Robert A.
- SEC CIK
- 0001992908
No open-market purchases or sales filed in the past year.
Current role at each company
- NBP NovaBridge BiosciencesDirectoras of Aug 25, 2026
- LBRX LB Pharmaceuticals IncDirectoras of Jun 5, 2026
- NMRA Neumora Therapeutics, Inc.Head of R&Das of Feb 20, 2025
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Lenz Robert A. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
NMRA Neumora Therapeutics, Inc.
Head of R&D4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2025 (view filing) | Feb 18 | 2 days | Lenz Robert A.Head of R&D | SSale | −5.61K | $1.67 | −$9.38K | −1.8%309.1K after | 10b5-1 |
| Oct 11, 2024 (view filing) | Oct 9-10 | 2 days | Lenz Robert A.Head of R&D | SSale | −13.8K | $15.06 | −$208.1K | −4.2%314.7K after | 2 lots10b5-1 |
| Sep 19, 2024 (view filing) | Sep 17-18 | 2 days | Lenz Robert A.Head of R&D | SSale | −41.5K | $11.88 | −$492.7K | −11.2%328.5K after | 2 lots10b5-1 |
| Sep 16, 2024 (view filing) | Sep 12 | 4 days | Lenz Robert A.Head of R&D | SSale | −32.9K | $11.43 | −$376.6K | −8.2%370.0K after | 10b5-1 |